Monoclonal antibody against ependymoma-derived cell line

Area of Science:

• Oncology
• Immunology
• Neuroscience

Background:

• Ependymomas are a type of glioma, a tumor that arises from the glial cells that support nerve cells.
• Developing specific biomarkers for accurate diagnosis and targeted therapy is crucial for improving patient outcomes.

Purpose of the Study:

• To generate and characterize a novel monoclonal antibody (MAb) that specifically recognizes an antigen on ependymoma cells.
• To evaluate the specificity of the MAb against various brain tumor cell lines and normal tissues.

Main Methods:

• Hybridoma technology was used to produce MAbs against the human ependymoma cell line KMS II.
• Enzyme-linked immunosorbent assay (ELISA), indirect immunofluorescence, and immuno-electron microscopy were employed to assess MAb specificity and antigen localization.
• Immunoperoxidase staining and absorption assays were performed on tumor tissues and normal brain samples.

Main Results:

• A specific MAb, Ep-C4 (IgG1), was identified that reacted with ependymoma cell lines but not with other brain tumor types, neuroblastoma, carcinoma, or hematopoietic cell lines.
• The antigen recognized by Ep-C4 is a cell surface membrane protein of 81,000 daltons.
• Ep-C4 showed no cross-reactivity with normal adult or fetal brain tissues.

Conclusions:

• The MAb Ep-C4 defines an antigen that is specific to ependymoma cells.
• This MAb represents a potential diagnostic tool for ependymoma, differentiating it from other neuroectodermal tumors.